It’s a good start to the new year, and we’re going to get off to a great start!Xinlandao (Tianjin) Medical Technology Co., Ltd. and Promed Genetic Medical Device R&D and Production Base Project were put into operation

The plan for the year begins in spring, and it is the right time to show off the "rabbit". On the eighth day of the first lunar month, the day after the Spring Festival, the research and development invested and constructed by Xinlandao (Tianjin) Medical Technology Co., Ltd., a subsidiary of Beijing Promed Gene Medical Technology Co., Ltd. The production base was officially put into operation.Li Quanli, Party Secretary and Director of Huaming High-tech Zone Service Center, Li Dongping and Li Li, partners of Haiyin Capital, and Yang Mu, executive general manager of Zhixin (Tianjin) Technology Business Incubator Co., Ltd., attended the ceremony.

At the ceremony, Wang Bingyu, Chairman of Beijing Hongbo Gene Medical Technology Co., Ltd., Li Dongping, Partner of Haiyin Capital, and Li Quanli, Party Secretary and Director of Huaming High-tech Zone Service Center, delivered speeches.Wang Bingyu said that from site selection to base construction and rapid implementation, the project cannot be separated from the strong support and professional services of Zhixin Incubator, Haiyin Capital and Huaming High-tech Zone. Xinlandao will rely on the good industrial foundation of the High-tech Zone to develop the project as soon as possible. Put into production, increase research and development efforts, and develop rapidly with the high-tech zone.Li Quanli said that the implementation of the Hongbo Gene R&D and Production Base project is an affirmation of the industrial environment, policies, supporting services, etc. of the High-tech Zone. It is also an important step for the High-tech Zone and Zhixin Incubator and Haiyin Capital to provide professional services

After the speech, under the witness of all the leaders, Xinlandao signed technical cooperation and entrusted production contracts with Germany's Miji Medical and Beijing Weidu Medical respectively.At the end of the event, the guests visited the Hongbo Gene R&D and production base.

The Promed Gene Medical Device R&D and Production Base Project is invested by Beijing Promed Gene Medical Technology Co., Ltd. (hereinafter referred to as "Hongbo Gene"). Promed Gene was established in 2015 and is a company listed on the New OTC Market. It is a research and development, production , an IVD company integrating professional marketing, focusing on the point-of-care rapid test market (POCT), developing instruments, equipment and detection reagents in the fields of molecular diagnosis POCT and chemiluminescence immunoassay POCT, and developing towards intelligence and wearables .After the project is officially put into operation, the output value is expected to reach 500 million yuan in 2025.